| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.036 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.063 | 0.8 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |